🔎 Trials Near Me

Почетна › Рак дојке › Тенеси

Kliničke studije za Рак дојке u državi Тенеси

90 studija za Рак дојке traži učesnike na lokacijama u državi Тенеси.

Gradovi u državi Тенеси

Zvanični tekst studije (na engleskom)

A Study Evaluating the Safety of Inavolisib and Fulvestrant With or Without Palbociclib in Participants With Advanced Breast Cancer (ABC) and Type 2 Diabetes

  • West Cancer Center & Research Institute, Germantown
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 13. 11. 2026. · NCT07748208

Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)

  • SCRI Oncology Partners ( Site 7000), Nashville
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 12. 11. 2026. · NCT06797635

Post-Marketing Study for Early-Stage Low-Risk Breast Cancer Treatment Using ProSense® Cryoablation (ChoICE Trial)

  • The West Clinic, PC dba West Cancer Center, Germantown
Тражи се учесник
Узраст 70 и старији · Оба пола · Ажурирано 12. 11. 2026. · NCT07629206

S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity

  • Baptist Memorial Hospital and Cancer Center-Memphis, Memphis
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 12. 11. 2026. · NCT03418961

A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer

  • Greco Hainsworth Center for Research Tennessee Oncology, Nashville
  • SCRI Oncology Partners, Nashville
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 10. 11. 2026. · NCT06827236

A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

  • Tennessee Cancer Specialists ( Site 7001), Knoxville
  • SCRI Oncology Partners ( Site 7005), Nashville
  • Nashville General Hospital ( Site 0017), Nashville
  • и још 1
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 10. 11. 2026. · NCT06966700

Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors

  • Sarah Cannon Research Institute - Pharmacy, Nashville
  • SCRI Oncology Partners, Nashville
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 10. 11. 2026. · NCT04557449

Gene Signatures to Guide HR+MBC Therapy in a Diverse Cohort

  • West Cancer Center (Margaret West Comprehensive Breast Center), Memphis
  • Vanderbilt University/Ingram Cancer Center, Nashville
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 6. 11. 2026. · NCT05693766

A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer

  • Tennessee Oncology - Chattanooga Oncology & Hematology Associates, Chattanooga
  • The West Clinic, Germantown
  • Tennessee Oncology PLLC, Nashville
  • и још 1
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 6. 11. 2026. · NCT03424005

Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

  • Baptist Cancer Center - Memphis, Memphis
  • SCRI Oncology Partners, Nashville
  • Tennessee Oncology, Pllc, Nashville
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 5. 11. 2026. · NCT06324357

Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer

  • West Cancer Center, Germantown
  • Vanderbilt, Nashville
Тражи се учесник
Узраст 18 и старији · Оба пола · Ажурирано 5. 11. 2026. · NCT07214532

Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer

  • Tennessee Cancer Specialists, Knoxville
  • Tennessee Oncology, PLLC, Nashville
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 5. 11. 2026. · NCT06982521

A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

  • Sarah Cannon Research Institute SCRI, Nashville
  • Nashville General Hospital, Nashville
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 4. 11. 2026. · NCT07174336

A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer

  • West Cancer Center, Germantown
  • Vanderbilt University Medical Center, Nashville
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 4. 11. 2026. · NCT06790693

E-Mindfulness Approaches for Living After Breast Cancer

  • University of Tennessee - Knoxville, Knoxville
  • Baptist Memorial Hospital and Cancer Center-Memphis, Memphis
  • Vanderbilt Breast Center at One Hundred Oaks, Nashville
Тражи се учесникФаза 3
Узраст од 18 до 50 · Оба пола · Ажурирано 4. 11. 2026. · NCT06748222

A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer

  • Tennessee Oncology, Nashville
Тражи се учесникФаза 2
Узраст 18 и старији · Жене · Ажурирано 4. 11. 2026. · NCT07287098

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

  • Sarah Cannon Research Institute at Tennessee Oncology, Nashville
  • Tennessee Oncology, Nashville
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 4. 11. 2026. · NCT05579366

Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics

  • Baptist Memorial Hospital and Cancer Center-Collierville, Collierville
  • Baptist Memorial Hospital and Cancer Center-Memphis, Memphis
  • Baptist Memorial Hospital for Women, Memphis
Тражи се учесникОпсервациона студија
Узраст 18 и старији · Оба пола · Ажурирано 4. 11. 2026. · NCT06418204

A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)

  • SCRI Oncology Partners, Nashville
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 4. 11. 2026. · NCT06760819

Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

  • Baptist Memorial Hospital and Cancer Center-Collierville, Collierville
  • The West Clinic - Wolf River, Germantown
  • University of Tennessee - Knoxville, Knoxville
  • и још 1
Тражи се учесникФаза 3
Узраст од 18 до 60 · Жене · Ажурирано 4. 11. 2026. · NCT05879926

A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors

  • SCRI Oncology Partners, Nashville
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 4. 11. 2026. · NCT06695845

A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)

  • SCRI Oncology Partners ( Site 7000), Nashville
  • Tennessee Oncology ( Site 0068), Nashville
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 3. 11. 2026. · NCT07060807

A Study of JNJ-101684362 (HLD-0117) in Patients With Metastatic Breast Cancer

  • SCRI Oncology Partners, Nashville
Тражи се учесникФаза 1
Узраст 18 и старији · Жене · Ажурирано 3. 11. 2026. · NCT07524855

The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study

  • Baptist Memorial Healthcare, Memphis
Тражи се учесникФаза 3
Узраст 60 и старији · Оба пола · Ажурирано 2. 11. 2026. · NCT06377852

ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer

  • The West Clinic, P.C. dba West Cancer Center, Germantown
  • Tennessee Oncology, Nashville
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 30. 10. 2026. · NCT07173751

Cancer Pain Management Using a Web-based Intervention

  • Vanderbilt University, Nashville
Тражи се учесник
Узраст 18 и старији · Жене · Ажурирано 30. 10. 2026. · NCT06085313

Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

  • Tennessee Oncology PLLC, Nashville
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 29. 10. 2026. · NCT07288359

A Phase 1 Study of LNCB74 in Advanced Solid Tumors

  • Sarah Cannon Research Institute, Nashville
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 29. 10. 2026. · NCT06774963

A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer

  • Sarah Cannon Research Institute (Nashville), Nashville
  • Vanderbilt University Medical Center, Nashville
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 29. 10. 2026. · NCT07102381

A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations

  • Sarah Cannon Nashville, Nashville
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 28. 10. 2026. · NCT07109726

EXActDNA-003 / NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD)

  • Ballad Health Cancer Center, Kingsport
Тражи се учесникОпсервациона студија
Узраст 18 и старији · Оба пола · Ажурирано 27. 10. 2026. · NCT06401421

A Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast Cancer

  • West Cancer Center, Germantown
Тражи се учесникФаза 2
Узраст 18 и старији · Жене · Ажурирано 26. 10. 2026. · NCT07054190

A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

  • SCRI Oncology Partners, Nashville
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 26. 10. 2026. · NCT06172478

A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer

  • Tennesse Oncology - Mt. Juliet Clinic, Mount Juliet
  • Vanderbilt Breast Center at One Hundred Oaks, Nashville
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 26. 10. 2026. · NCT07100106

A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors

  • SCRI Oncology Partners - Nashville, Nashville
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 22. 10. 2026. · NCT07383506

A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors

  • Tennessee Oncology, Nashville
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 22. 10. 2026. · NCT07287995

Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors

  • Sarah Cannon Research Institute Oncology Partners, Nashville
  • Vanderbilt-Ingram Cancer Institute, Nashville
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 22. 10. 2026. · NCT07287917

A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer

  • Research Site, Nashville
Тражи се учесникФаза 3
Узраст од 18 до 130 · Оба пола · Ажурирано 19. 10. 2026. · NCT07647328

A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.

  • The West Clinic, PLLC dba West Cancer Center, Germantown
  • Sarah Cannon Research Institute - Pharmacy, Nashville
  • SCRI Oncology Partners, Nashville
  • и још 2
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 19. 10. 2026. · NCT07062965

T-DXd Based Therapy Followed by Endocrine Therapy Plus Dual HER2 Blockade in First-line HER2+/ HR+ Metastatic Breast Cancer and Retreatment With T-DXd

  • SCRI Oncology Partners, Nashville
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 16. 10. 2026. · NCT07683754

Sa sajta ClinicalTrials.gov, podaci preuzeti 15. 11. 2026.. Svaka studija ima svoje kriterijume za uključivanje; tim studije odlučuje ko može da učestvuje.